Literature DB >> 12754558

Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy: initial experience in the Federal District.

Evandro César Vidal Osterne1, Tamer Najar Seixas, Walter Paulo Filho, Ernesto Misael Cintra Osterne, Otoni Moreira Gomes.   

Abstract

OBJECTIVE: To analyze the efficacy of percutaneous transluminal septal alcoholization in the treatment of refractory obstructive hypertrophic cardiomyopathy (HOC).
METHODS: The patients were referred for alcoholization after Doppler echocardiography. Before and after alcoholization, the intraventricular pressure gradient was recorded. Alcoholization was performed with a 3mL injection of absolute alcohol through a coronary angioplasty balloon catheter. The procedure was concluded after a significant reduction or abolition of the pressure gradient.
RESULTS: Of 22 patients, 18 (81.8%) successfully concluded the procedure with a reduction in intraventricular pressure gradient at baseline (from 67.6+/-24.2 mmHg to 3.8+/-1.9 mmHg, p<0.005) and after extrasystole (from 110.4+/-24.2 mmHg to 9.6+/-2.6 mm Hg, p<0.005). A significant reduction in mean interventricular septal thickness (from 2+/-0.3 mm to 1.7+/-0.2 mm, p<0.005) and in peak pressure gradient (from 90.7+/-23.5 mmHg to 6.1+/-1.4 mmHg, p<0.005) was observed on Doppler echocardiography after 6 months, when all patients were in functional class I. The most frequent acute complication, present in 11% of the patients, was the need for definitive pacing implantation. Relapse of the symptoms and reappearance of the pressure gradient occurred in 16.6% of the patients. One patient (5.5%) died probably due to a diffuse coronary spasm prior to the procedure, and another died suddenly on late follow-up.
CONCLUSION: Percutaneous transluminal septal alcoholization is effective and safe in the treatment of HOC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754558     DOI: 10.1590/s0066-782x2003000400002

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  1 in total

1.  Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy.

Authors:  Travis J Moss; Matthew M Zipse; Mori J Krantz; William H Sauer; Ernesto E Salcedo; Joseph L Schuller
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-11       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.